The effect of Lazaroid U-74389G on extended liver resection with ischemia in dogs.
In liver surgery, total clamping of the portal triad (Pringle's procedure) is commonly used, and it sometimes causes liver failure. This study was designed to evaluate the effect of Lazaroid U-74389G (LAZ-G), which inhibits iron-dependent lipid peroxidation, on ischemia-reperfusion injury during liver resection in dogs.



The experiment animals were divided into 2 groups. The control group was subjected to 60 minutes of warm ischemia by partial inflow occlusion. The LAZ-G-treated group received LAZ-G before ischemia and then underwent liver ischemia. After reperfusion, the nonischemic lobes were resected, and the remnant liver function was evaluated.



The LAZ-G-treated group showed a significantly improved animal survival rate. Biochemical analysis and morphologic evaluation by electron microscopy suggest that LAZ-G pretreatment protects both hepatic parenchymal cells and sinusoidal endothelial cells from ischemia-reperfusion injury. Expression of IL-1 beta messenger RNA in hepatic venous blood was measured by a reverse transcriptase-polymerase chain reaction; it was shown to be inhibited in the LAZ-G-treated group after reperfusion. This suggests that LAZ-G decreases the activation of proinflammatory cytokine expression.



Lazaroid U-74389G ameliorates ischemia-reperfusion injury caused by Pringle's procedure during extensive liver resection. This agent may therefore be clinically applicable for extended liver surgery involving vascular isolation.
Iwanami
K
K
Second Department of Surgery, Gunma University School of Medicine, Japan.
Takeyoshi
I
I
Ohwada
S
S
Kobayashi
J
J
Kawashima
Y
Y
Aiba
M
M
Matsumoto
K
K
Morishita
Y
Y
D000818:Animals; D004285:Dogs; D005260:Female; D006498:Hepatectomy / Q000009:adverse effects / Q000379:methods; D006503:Hepatic Veins; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007375:Interleukin-1 / Q000235:genetics; D007511:Ischemia / Q000517:prevention & control*; D008099:Liver / Q000098:blood supply* / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D017093:Liver Failure / Q000517:prevention & control; D008297:Male; D011281:Pregnatrienes / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000097:blood; D015427:Reperfusion Injury / Q000517:prevention & control
D007166:Immunosuppressive Agents; D007375:Interleukin-1; D011281:Pregnatrienes; D012333:RNA, Messenger; C074965:U 74389F